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Abstract 
Objectives: In current management paradigms of Rheumatoid Arthritis (RA), patient global assessment 
(PGA) is crucial to decide whether a patient has attained remission (target) or needs reinforced 
therapy. We investigated whether the clinical and psychological determinants of PGA are appropriate 
to support this important role. 
Methods: This was a cross-sectional, single centre study including consecutive ambulatory RA patients. 
Data collection comprised swollen (SJC28) and tender joint counts (TJC28), C-Reactive protein (CRP), 
PGA, pain, fatigue, function, anxiety, depression, happiness, personality traits, and comorbidities. 
Remission was categorised using ACR/EULAR Boolean-based criteria: remission, near-remission (only 
PGA>1) and non-remission. A binary definition without PGA (3v-Remission) was also studied. 
Univariable and multivariable analyses were used to identify explanatory variables of PGA in each 
remission state.  
Results: 309 patients were included (remission: 9.4%; near-remission: 37.2%; non-remission: 53.4%). 
Patients in near-remission were indistinguishable from remission regarding disease activity, but 
described a disease impact similar to those in non-remission. In multivariable analyses, PGA in near-
remission was explained (R2adjusted=.50) by fatigue, pain, anxiety and function. Fatigue and pain had no 
relationship with disease activity measures. 
Conclusion: In RA, a consensually acceptable level of disease activity (SJC28, TJC28, and CRP≤1) does 
not equate to low disease impact: a large proportion of these patients are considered in non-remission 
solely due to PGA. PGA mainly reflects fatigue, pain, function, and psychological domains, which are 
inadequate to define the target for immunosuppressive therapy. This suggests that clinical practice 
should be guided by two separate remission targets: inflammation (3v-Remission) and disease impact.  
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Significance and Innovations 
 In Rheumatoid Arthritis, Patient Global Assessment (PGA) is frequently the sole criterion impeding 
patients from achieving the target of remission as defined by the ACR/EULAR Boolean-based 
criteria ("4v-Remission"). 
 A large proportion of patients with tight control of inflammation maintain a high PGA and this 
cannot be improved by further disease control.  
 We, therefore, propose that an alternative definition of remission, based solely on joint counts 
and C-reactive protein ("3v-Remission"), is more appropriate to define the target for 
immunosuppressive therapy.  
 Patients’ perspective should remain core to disease assessment and management, but this will be 
better served by more discriminative instruments than PGA. 
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Introduction 
The outlook of RA has improved remarkably over recent years, due to not only the 
development of new therapies but also novel treatment strategies (1). Among these, the Treat-to-
Target (T2T) recommendation (2, 3) epitomizes the consensual concept that disease treatment should 
aim at achieving, as early and consistently as possible, a target of level of remission, or at least low 
disease activity (3, 4).  
The provisional definition of remission in rheumatoid arthritis proposed conjunctly by the 
American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR)(5), 
has been recommended for use in daily care of RA patients (3). This definition takes into consideration, 
in a Boolean format, swollen and tender joint counts (SJC28, TJC28), CRP and patient global assessment 
(PGA). PGA weights the same as the other components, which are more closely related to disease 
activity (inflammation). The ethical and clinical imperative of incorporating patient reported outcomes 
(PROs) in the decision process is indisputable, but reflection is needed on the best way to achieve this 
(6).  PGA's inclusion was mainly justified because it represents the patient's perspective and is 
responsive to treatment in clinical trials, discriminating between active and control intervention (5). 
However, considering stopping progression of joint damage is one of the most important objectives of 
treatment in RA, a recent systematic review (7) concluded that only SJC and acute phase reactants, but 
not PGA, were independent predictors of radiographic progression. Another point against PGA is its 
difficult interpretation (8-10). Until now, most studies suggest that PGA essentially reflects pain, 
function and fatigue (10-15), which in turn have shown a variable correlation with inflammatory 
markers, in studies that did include psychosocial dimensions or perform multivariable analyses. 
Considerable percentages of PGA remain unexplained (>22%)(11) and few studies have explored its 
relationship with the underlying level of disease activity (10), or with the patient’s psychological profile 
(10, 16, 17).   
PGA has been identified as the main single factor impeding patients from reaching the state of 
remission (9, 18-20). These patients represent 61% to 80% of all those who do not reach the 
ACR/EULAR Boolean remission due to one single parameter being >1, a state that has been designated 
as "near-remission" (18). Similar to patients in remission, they have a maximum of 1 SJC, 1 TJC and 1 
mg/dl PCR. However, according to the ACR/EULAR definition they will be considered in non-remission, 
because of PGA>1, thus becoming candidates for reinforced immunosuppressive therapy, following 
the current treatment guidelines (3, 4).  
The key clinical question we want to address is whether such patients require an increase in 
immunosuppressive therapy or would be best treated with alternative interventions directed at the 
causes of high-perceived disease impact. In order to answer this crucial clinical question it is essential 
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to understand whether PGA conveys dimensions of the disease that are amenable to change by 
immunosuppressive therapy, especially in patients in near-remission.  
The objectives of the present study were to: (i) understand how PGA correlates with a broad 
array of variables, from disease activity, comorbidities, psychological dimensions, and other measures 
of disease impact in people with RA; (ii) determine whether these components of PGA variability 
change in different remission state categories, especially in near-remission thus impacting upon T2T 
driven decisions; (iii) understand the explanatory variables for pain and fatigue, and (iv) explore the 
adequacy of a remission definition without PGA (3v-remission) as a basis to define the target for 
immunosuppressive therapy, separating it from disease impact.  
 
Participants and Methods 
Study design & Setting 
This was an observational, cross-sectional study, performed in a single rheumatology 
outpatient department, in Portugal between September and December 2015. 
 
Participants 
Consecutive adult patients satisfying current RA criteria (21, 22) were invited to participate. 
Patients were excluded only if they were unable to respond to the questionnaires unaided. Patients 
are followed, monitored and treated according to standard Department’s guidelines. Ethical approval 
was granted by the University of Coimbra’s Faculty of Medicine Ethics Committee (CE-037/2015) and 
all patients signed an informed consent form before start of study procedures.  
 
Patient global assessment 
PGA was assessed using two different formulations: (a) as stated in the ACR/EULAR definition 
of remission (5) - “Considering all the ways your arthritis has affected you, how do you feel your 
arthritis is today?", and (b) as stated in the Disease Activity Score using 28 joints (DAS28) definition 
(23) - "How active was your arthritis during the past week?". Both were presented as a 0-100 mm visual 
analogue scale (VAS) as recommended, with their respective anchors: “very well” and “very poor” for 
the former and "not active at all" and "extremely active" for the latter. Each formulation of PGA was 
presented in a single page of the questionnaire, interspersed with other PROs. The first formulation 
was used to define the ACR/EULAR remission status and was also taken as the dependent variable in 
all analyses. 
 
Other Variables 
Patients responded to questionnaires including demographic data and the following PROs: 
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pain [Numerical Rating Scale (NRS), range 0–10], fatigue (NRS, range 0–10), function (Health 
Assessment Questionnaire (24)), anxiety and depression  (Hospital Anxiety and Depression Scale (25)), 
happiness, through the Subjective Happiness Scale (26), a 4-item measure (7-point Likert scale). 
Personality was assessed with the Ten Item Personality Inventory (27), a brief measure of the Big-Five 
personality dimensions, each being scored as the mean of 2 items (7-point Likert scale). For both the 
latter measures, higher means correspond to more intense expression of the respective conditions. 
The attending physician collected the following: year of diagnosis, rheumatoid factor and ACPA 
status, presence/absence of erosions, TJC28, JC28, CRP, physician global assessment of disease activity 
(0-100mm VAS), and current medications. Concomitant diagnoses were registered (fibromyalgia, 
depression, low back pain, osteoporotic fractures, osteoarthritis, and stroke) and the total number of 
comorbidities was computed. 
Patients completed the questionnaires unaided and before clinical consultation in order to 
minimise the influence of physician’s assessment. Both patients with experience of using VAS/NRS 
(54.7%) and those with no previous experience were included.  
 
Remission definitions 
Patient's remission state was classified in three categories derived from the ACR/EULAR 2011 
Boolean-based definition(5): i) Remission (TJC28, SJC28, CRP mg/dl, and PGA, all ≤1), ii) Near-remission 
(18) (TJC28, SJC28, and CRP mg/dl ≤1; PGA>1), iii) Non-remission (TJC28 or SJC28 or CRP mg/dl >1). In 
addition, we explored the binary definition 3v Remission (28) (TJC28, SJC28, and CRP mg/dl ≤1; where 
PGA is excluded from consideration).  
The DAS28-CRP(3v) considers TJC, SJC and CRP. The 3v version excludes the consideration of 
PGA, as required for the purposes of this study. We used the variant with CRP as this is more readily 
available in this medical centre than the erythrocyte sedimentation rate. 
 
Statistical methods 
Quantitative data were expressed as means (SD) and categorical data as frequencies and 
percentages. There was no imputation of missing data.  
Pearson’s correlation coefficients between PGA, and pain, fatigue and all potentially 
explanatory continuous variables were calculated. Correlations were categorized as very good, r≥.60; 
moderate, r=.40-.59 and poor r<.40 (29). Differences in variables between remission state categories 
were tested in pairs using Independent Student’s t-test, with adjustment for relevant cofactors 
(ANCOVA) where appropriate. Variables with p<.10 in the overall sample, and patients with full sets of 
data were included in stepwise multivariable linear regression models (backward method) with PGA 
as dependent variable. Two methods were used to prevent multicollinearity between explanatory 
variables in the multivariable models: i) assessment of bivariate correlations of possible explanatory 
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variables prior to inclusion, defining r<.80 as the threshold for inclusion (30); ii) assessment of the 
variance inflation factor, assuming values <4 as acceptable (30). None of the variables was excluded 
based on these criteria. These multivariable linear regression analyses were performed for the overall 
sample. They were then repeated, using the same variables, for subsamples defined by the different 
disease remission states. Regarding sample size, we established that a minimum of 10-15 patients per 
each explanatory variable should be recruited (total 200-300 patients) as recommended by Austin and 
Steyerberg (31).  
IBM® SPSS® Statistics, version 20.0 software was used for all analyses. 
 
Results 
Patient characteristics 
In total, 309 RA patients were included. Reasons for exclusion are presented in Supplementary 
Figure 1.  
Demographic and clinical characteristics of patients are presented in Table 1. A total of 79 
(25.6%) patients had no comorbidities and 5 accumulated a maximum of five comorbidities (data not 
shown). The mean (SD) DAS28-CRP(3v) was 2.5 (0.9) and the mean PGA was 43.7 (26.7). Regarding 
remission state, only 29 (9.4%) patients satisfied the ACR/EULAR criteria for remission. All remaining 
patients, in non-remission, were split according to the criteria described above, into near-remission 
115 (37.2%) and non-remission 165 (53.4%). If PGA was not considered in the definition (3v-
Remission), the rate of patients classified in remission would increase from 9.4% to 46.6%. 
 
Disease activity and disease impact across remission state categories 
The comparison between remission state categories (Table 2) shows that near-remission is 
almost indistinguishable from remission in terms of disease activity measures, except for a slightly 
higher TJC28. Conversely, in terms of disease impact (PROs), near-remission is clearly distinct from 
remission but quite similar to non-remission. For instance, PGA in near-remission and non-remission 
is 10 and 11 fold, respectively, of the PGA reported by patients in remission. 
When comparing all patients with TJC28, SJC28, and CRP (mg/dl) ≤1 (3v-Remission) versus 
those with at least one of these parameters >1 (3v-Non-remission) the differences were equally clear-
cut in terms of disease activity (Supplementary Table S1). Conversely, the disease impact measures 
largely overlap between these two categories (see also Table 2). 
Anxiety and depression were present at similar levels in near-remission and non-remission, 
but were significantly lower in remission. Happiness followed a similar pattern but did not reach 
statistical significance (Table 2).  
 
8 
 
PGA correlates across remission state categories - univariable analyses 
Overall, there were significant correlations between PGA and all continuous variables included, 
except for the personality domains “agreeableness” and "conscientiousness" (Table 3).  These 
correlations were classifiable as "good" for pain, fatigue, and function and “moderate” for depression 
and anxiety. The remaining correlations were "poor", including not only personality traits but also all 
variables representing disease activity. Looking at the correlations between PGA and explanatory 
variables by disease states, near-remission was similar to non-remission in showing significant 
correlation between PGA and all PROs, including subjective happiness. In remission however, only 
fatigue and anxiety were significantly correlated with PGA. In both non-remission and in remission, 
PGA was significantly correlated with CRP and DAS28-CRP(3v) but this was not the case in near-
remission (Table 3).  
The correlation between personality traits and PGA was largely absent or poor, except in the 
remission group were "openness to experience" had moderate correlation with PGA. Overall, age, 
disease duration and number of comorbidities were all significantly correlated with PGA in univariable 
analyses and, variably, in the remission state categories. Years of formal education were inversely 
correlated with PGA in all groups (Table 3). 
In the overall sample, a significantly higher PGA was observed in association with the presence 
of erosions and of each of the comorbidities considered, except osteoporotic fractures (p=.055). There 
were no significant differences in PGA by gender, RF and ACPA status or familiarity with VAS/NRS 
(Supplementary Table S2).  
 
Correlates of PGA across remission states - multivariable analyses 
The explanatory variables of PGA differed between the three remission state categories. The 
best-fit model for near-remission (R2adjusted=.50), included fatigue, pain, anxiety and function. None of 
the objective measures of disease activity was retained (Table 4). In non-remission, the model 
(R2adjusted=.62) retained function, pain, anxiety, SJC28 and years of formal education. Age, disease 
duration, depression, happiness, personality traits, number of comorbidities, and CRP were not 
retained in the multivariable models for any of the remission state categories. 
 
The correlates of pain and fatigue  
The origins of pain and fatigue, the most important correlates of PGA in near-remission 
patients were statistically explored through univariable (Supplementary Table S3) and multivariable 
analyses. Patients in non-remission were also studied, for comparison. In the multivariable analyses 
(Table 5), pain was poorly explained in both near-remission (R2adjusted=.51) and in non-remission 
(R2adjusted=.54). The best-fit models are different in the two remission states, including fatigue, anxiety, 
years of formal education and extraversion for patient in near-remission while for those in non-
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remission, the latter two are substituted by function and happiness. The correlates of fatigue in best-
fit models include pain and function for both remission state categories. In near-remission, two 
personality traits are also retained in the model, having a significant correlation with fatigue, whereas 
in non-remission, personality traits are dropped and anxiety is retained, increasing fatigue. 
None of the disease activity measures have a significant relationship with either pain or 
fatigue irrespective of the remission state category.  
 
Discussion 
This is one of very few studies assessing PGA correlates across remission state categories and 
the first using the Boolean-based definition for this purpose. The results confirm previous observations 
(9, 18-20) that a large percentage of RA patients in routine clinical practice miss the target of remission 
solely because of PGA. The percentage of near-remission observed (37.2%) was higher than reported 
before: 14.4% to 34.1% (9, 15, 17, 18, 20). These differences may be related to cultural issues (32, 33) 
but the level of education and prevalence of emotional distress may also play a role.  Whatever the 
reason, none of these percentages is negligible, as they could lead to different and potentially 
hazardous therapeutic decisions according to the current RA management recommendations. In this 
study it represents a five-fold increase (from 9.4% to 46.6%) in the rate of remission. 
PGA from patients in near-remission is not associated with disease activity but rather with 
fatigue, pain, anxiety and function. Pain and fatigue, in turn, were correlated among them, and were 
influenced by anxiety, personality traits and happiness, but bear no relationship with SJC28 or CRP 
(Table 5). These observations are in close agreement with the findings reported by Ward et al. (10).  
In other studies (9-15, 19) pain has been shown to be the best "predictor" of PGA, regardless 
of remission state. In the current study, pain was second to fatigue in explaining PGA in near-remission. 
Using a similar near-remission definition to ours, Studenic et al. (18) demonstrated that higher pain 
levels lead to patients failing the ACR/EULAR Boolean-based definition only due to PGA. Ward, Guthrie 
and Dasgupta (10) concluded that pain severity is the strongest determinant of PGA, not only directly, 
but also indirectly via deteriorated function, DAS28, and health distress (10).  
In essence, the results of our study confirm and expand previous observations, and conjunctly 
they underline that, in near-remission, PGA seems to convey and be driven by dimensions that are not 
obviously related to the inflammatory process therefore, cannot be expected to change because of 
reinforced immunosuppressive therapy. 
This does not imply that PGA is not correlated with disease activity, as argued to support the 
inclusion of this parameter in the ACR/EULAR definition of remission (5). In fact, PGA was also 
correlated, although just moderately, with DAS28-CRP(3v) in this study (Table 3). Interestingly, this was 
true for the overall population (r=.36), for patients in non-remission (r=.30) and even for patients in 
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remission (r=.47), despite the very low level of disease activity and PGA (≤1) in the latter group. 
However, this was not the case in near-remission. PGA seems, therefore, to be in accordance with 
disease activity in both the remission and the non-remission group, but there is a clear mismatch 
between these dimensions in the near-remission group. These weak correlations between PGA and 
disease activity parameters reflect that there is no meaningful relationship on the individual level. This 
does not mean, in any way, that the patient’s perspective is not important. On the contrary! It is 
essential to care, as we discuss below. 
The conclusions of this study need to be considered in the light of potential limitations. First, 
our population was recruited in a single centre in Portugal, which may limit generalizability as PGA and 
other PROs have been shown to vary across countries (33-35). The similarity of our findings with other 
studies is however rather reassuring in this respect. Second, the mean DAS28 in this sample was very 
low (mean=2.5, SD=0.9), reflecting a well-controlled disease cohort. Samples with higher mean DAS28 
may have a lower percentage of near-remission patients. However, our analyses were performed by 
disease activity subgroups and these conclusions are probably applicable to other similar disease 
activity strata. Pharmacological treatment used in our sample may also differ from other countries 
(36), but we believe that this does not affect the main results or the conclusions of this study. Third, 
its cross-sectional nature limits the ability to assess causality and progress over time. Fourth, the 
overall model explained only 62% of PGA. This may be due to an inherent characteristic of the outcome 
or some relevant variables not being assessed, such as stiffness (13) work disability (37) or joints of the 
feet, although these were not a significant factor in the study by Studenic’s et al. (18). Finally, analyses 
within the remission group are weakened by the small size of the group and the limited range of 
disease activity parameters and PGA allowed by the definition (all ≤1).  
Conversely, the study presents a very robust and complete set of data, including domains that 
most physicians consider highly relevant but are seldom studied, like personality traits and emotional 
states. The sample included a wide diversity of age, disease activity, years of formal education and 
previous experience with questionnaires and VAS, all of these being potentially relevant dimensions, 
rarely represented with a range that allows proper statistical evaluation. Additionally, contrary to 
previous studies, we used the different formulations of PGA approved for each instrument, as this may 
affect the results (38, 39). Finally, our sample was also powered to allow strong statistical evaluation 
and was composed of unselected ambulatory patients.  
 
The clinical implications of these observations are far-reaching. This study demonstrates that 
non-remission state as defined by the ACR/EULAR 4v-Boolean concept brings together, due to a similar 
PGA, two different groups of patients in terms of disease activity: near-remission and non-remission 
(Table 2). This strongly supports the view that the target chosen to drive immunosuppressive therapy 
should not include PGA. In near-remission, the only targets that are appropriate for 
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immunosuppressive therapy (SJC, TJC, and CRP, i.e. 3v-Remission) have already been achieved, but 
including PGA in the definition obscures that fact and puts the patient at risk of excessive treatment. 
A sharp target for any therapy should be defined by parameters amenable to change by that same 
therapy. This is not the case for PGA regarding immunosuppression. 
 These observations call for a clear separation of the concepts of remission according to the 
objective of their use: control of inflammation (physicians’ remission, as a target for 
immunosuppressive therapy) and control of disease impact (patients’ remission, as target for overall 
management of the disease). The former offers a strong contribution but not a guarantee for the latter.  
The concept of 3v-remission provides the most appropriate definition for "physician's 
remission" as it results in two clearly separate and homogeneous groups of patients in terms of disease 
activity. For clarity, these concepts are presented in Figure 1.  
The importance of "patient's remission" cannot and should not be overlooked as controlling 
the impact of disease upon patients’ lives is the core objective of disease management. Given the 
relationship between disease activity and PGA described above, rheumatologists can be reassured that 
they will reduce disease impact in most patients, while controlling the disease process into remission. 
However, once TJC28, SJC28 and CRP are close to or below 1 but PGA remains high, it is obviously not 
the time to increase immunosuppressive therapy but rather to consider adjuvant therapies. Some 
adjuvant therapies have shown to improve several PGA-related variables. This is the case for non-
pharmacological interventions, such as cognitive-behavioural therapy (40, 41) and relaxation or 
biofeedback interventions (42) that address pain, functional disability, fatigue, sleep, depressive 
symptoms, anxiety, coping, self-efficacy, and even tender joints. Other non-pharmacological 
interventions that have been shown to be effective are physical activity (43, 44), occupational therapy 
(45) and patient education (46, 47). These studies highlight the importance of a team approach to 
disease management as well as the importance of incorporating patient's perspective in the overall 
treatment plan. PGA is not an appropriate instrument at this stage either, because it does not 
discriminate between the reasons for continued impact, which is essential to guide the selection of 
adjuvant therapy but can only provided by discriminating instruments, such as the RAID in its seven 
domains (48). 
Further investigation is needed to fully clarify these issues, including assessment of possible 
persistence of minimal inflammatory activity in patients in near remission and studies to determine 
whether a persistently high PGA in patients who are otherwise in remission has any impact upon long-
term structural damage. The TJC may also be affected by concomitant diseases (e.g. fibromyalgia) and 
other factors such as psychological status. Factors associated to a high TJC when SJC and CRP are ≤1 
also deserve investigation in future studies. Additional evidence and guidance is needed on the origins 
and best management strategies for pain, fatigue and other relevant domains of disease impact in RA. 
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In conclusion, this study demonstrates that in RA, control of inflammation does not equate to 
low disease impact. The impact of disease upon patients’ lives is predominantly independent from the 
degree of inflammation, especially in near-remission. The results of this study suggest that the 
concepts of disease activity and disease impact should be addressed as separate domains. A definition 
of remission focused on inflammatory activity (physician’s perspective, 3v-Remission) is the most 
appropriate to serve as target for immunosuppressive therapy. The patient's perspective, i.e., disease 
impact should be examined separately with more analytical measures than PGA, in order to guide 
efforts to alleviate impact beyond what is achieved through disease control. 
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Table 1 – Demographic and clinical characteristics of RA patients (n=309) 
Demographic  
 Age, years, mean (SD) 59.5 (12.3) 
Female gender, n (%) 253 (81.9) 
 Formal education, years, mean (SD)a 7.4 (4.5) 
Disease characteristics  
 Disease duration, years, mean (SD) 12.0 (9.0) 
RF positive, n (%)a 224 (74.2) 
ACPA positive, n (%)a 148 (69.8) 
Erosions, present, n (%)a 174 (69.6) 
Comorbidities, yes,  n (%)    
 Fibromyalgia 52 (16.8) 
Depression 66 (21.4) 
Low Back Pain 79 (25.6) 
Osteoporotic fractures 29 (9.4) 
Osteoarthritis 181 (58.8) 
Stroke 6 (1.9) 
Current Pharmacological Treatment, n (%) a  
  Synthetic disease modifying drug 275 (89.3) 
Biologic agents 95 (30.8) 
Glucocorticoids  212 (68.8) 
Disease activity measure, mean (SD)  
 TJC28 (0–28) 1.4 (2.9) 
SJC28 (0–28) 1.4 (2.5) 
CRP (mg/dl) 0.8 (1.4) 
DAS28-CRP(3v) (0–9.4) 2.5 (0.9) 
 PhGA (VAS, 0-100) 13.4 (15.2) 
Disease activity status, n (%)  
 Remission#, n (%) 29 (9.4) 
 Near-remission## 115 (37.2) 
 Non-Remission### 165 (53.4) 
 3v-Remission####  144 (46.6) 
Disease impact measures, mean (SD)¶  
 PGA (VAS, 0–100) 43.7 (26.7) 
Pain  (NRS, 0–10) 4.9 (2.5) 
Fatigue (NRS, 0–10) 5.1 (2.7) 
HAQ (0–3) 1.1 (0.7) 
HADS-Anxiety (0–21)a  8.4 (4.3) 
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HADS-Depression (0–21)a  7.3 (4.2) 
SHS (1–7)(a  4.8 (1.3) 
TIPI (1-7) a  
Extraversion 4.2 (1.5) 
Agreeableness 5.7 (1.2) 
Conscientiousness 5.7 (1.3) 
 Emotional Stability 3.6 (1.5) 
 Openness to Experience 4.5 (1.4) 
ACPA= anti-citrullinated antibody; CRP= C-reactive protein; DAS28= Disease Activity 
Score using 28 joints; HADS= Hospital Anxiety and Depression Scale; HAQ= Health 
Assessment Questionnaire; PGA= patient global assessment; PhGA= physician global 
assessment; RF= rheumatoid factor; SHS= Subjective Happiness Scale; SJC28= 
swollen joint counts using 28 joints; TIPI= Ten Item Personality Inventory; TJC2 = 
tender joint counts using 28 joints. 
a Percentages of patients with missing data were < 2.5%, except for ACPA (31.4%) 
and erosions (19.1%).  
# Remission = TJC28, SJC28, CRP mg/dl, and PGA all ≤1 
## Near-remission = TJC28, SJC28, and CRP mg/dl all ≤1; PGA>1 
### Non-remission (TJC28 or SJC28 or CRP mg/dl >1, irrespective of PGA value) 
#### 3v-Remission = TJC28, SJC28, and CRP mg/dl all ≤1; PGA not considered. It 
equates to merge " Remission" and " Near-remission" disease states. 
¶ For all, except SHS and TIPI, higher scores correspond to worse outcomes. 
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Table 2 – Adjusted comparison of disease activity measures and disease impact measures between 
remission state categories in RA patients (n=309) 
  
A) 
Remission  
n=29 
B) Near-
remission 
n=115 
C) Non-
Remission 
n=165 
Adjusted# p-values  
A vs B A vs C B vs C 
Disease activity measures, mean 
(SD) 
 
     
 TJC28 (0–28) 0.1 (0.3) 0.3 (0.4) 2.5 (3.7) .028 .005 <.001 
SJC28 (0–28) 0.2 (0.4) 0.2 (0.4) 2.5 (3.0) .449 <.001 <.001 
CRP (mg/dl) 0.2 (0.2) 0.3 (0.2) 1.3 (1.8) .133 .008 <.001 
DAS28-CRP(3v) (0–9.4) 1.7 (0.3) 1.8 (0.4) 3.0 (0.8) .165 <.001 <.001 
 PhGA (VAS, 0-100) 6.0 (10.2) 6.0 (8.5) 19.8 (16.6) .770 <.001 <.001 
Disease impact measures¶, mean 
(SD) 
 
     
 PGA (VAS, 0–100) 4.5 (3.2) 44.4 (22.3) 50.0 (26.2) <.001 <.001 .273 
Pain  (NRS, 0–10) 2.0 (2.1) 4.7 (2.3) 5.5 (2.3) <.001 <.001 .019 
Fatigue (NRS, 0–10) 1.8 (2.1) 5.1 (2.3) 5.7 (2.6) <.001 <.001 .208 
HAQ (0–3) 0.3 (0.5) 1.0 (0.7) 1.3 (0.7) <.001 <.001 <.001 
HADS-Anxiety (0–21) 5.3 (4.9) 8.5 (3.9) 8.9 (4.4) .004 .009 .924 
HADS-Depression (0–21) 3.3 (3.4) 7.0 (3.7) 8.2 (4.3) <.001 <.001 .091 
SHS (1–7) 5.4 (1.2) 4.9 (1.0) 4.6 (1.4) .154 .065 .072 
CRP = C-reactive protein; DAS28 = Disease Activity Score using 28 joints; HADS = Hospital Anxiety and 
Depression Scale; HAQ = Health Assessment Questionnaire; PGA = patient global assessment; PhGA = 
Physician global assessment; SHS = Subjective Happiness Scale; SJC28 = swollen joint counts using 28 joints; 
TJC28 = tender joint counts using 28 joints. 
# One-way ANCOVA test adjusted for: Age, gender, disease duration, years of formal education, and number 
of comorbidities. 
¶ For all, except for SHS, higher scores correspond to worse outcomes. 
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Table 3 – Pearson’s correlation coefficients between PGA and other outcome 
measures according to remission state categories in RA patients (n=309) 
 
All patients 
(n=309) 
r (p-value) 
Remission# 
(n=29) 
r (p-value) 
Near-Remission## 
(n=115) 
r (p-value) 
Non-
Remission### 
(n=165) 
r (p-value) 
Demographic    
 Age (years)   .26**   .03  .19*   .26* 
Disease duration (years) .16*  -.02  .24* .10 
Formal Education (years)  -.34**    -.40* -.24*    -.36** 
Nr of comorbidities  (0-6)   .36**   .19   .34**     .32** 
Disease activity measures     
 TJC28 (0–28)  .32**   .39* .12     .32** 
SJC28 (0–28) .16* .12 .02 .07 
CRP (mg/dl) .15*  .20 .09 .08 
DAS28-CRP(3v) (0–9.4)   .36**    .47* .16     .30** 
 PhGA (VAS, 0-100)   .22**  .04 .12 .13 
Disease impact measures¶     
 Pain (NRS: 0–10)   .67** .10      .59 **    .64** 
Fatigue (NRS: 0–10)   .67**      .65**      .62 **    .61** 
HAQ (0–3)   .65**  .22      .49 **    .67** 
HADS-Anxiety (0–21)   .53**    .43*      .42 **    .58** 
HADS-Depression (0–21)   .54**  .33      .36 **    .53** 
HSS (1–7)  -.29** -.05 -.30* -.21* 
TIPI (1-7)     
Extraversion  -.17*   .17 -.09 -.15 
Agreeableness  -.22 -.27  .08 -.06 
Conscientiousness  -.11 -.37 -.04 -.08 
Emotional Stability     -.25** -.13 -.16   -.24* 
Openness to Experience -.18*   -.53* -.09   -.16* 
CRP = C-reactive protein DAS28 = Disease Activity Score using 28 joints; HADS = Hospital Anxiety and 
Depression Scale; HAQ = Health Assessment Questionnaire; PGA = patient global assessment; PhGA = 
Physician global assessment; SHS = Subjective Happiness Scale; SJC28 = swollen joint counts using 28 
joints; TIPI = Ten Item Personality Inventory; TJC28 = tender joint counts using 28 joints. rp = 
Pearson’s correlation coefficient, where, ≥.60, .40-.59 and <.40 represent good, moderate and poor 
correlations respectively. 
¶ For all, except SHS and TIPI, higher values correspond to worse status. 
# Remission = TJC28, SJC28, CRP mg/dl, and PGA all ≤1 
## Near-remission = TJC28, SJC28, and CRP mg/dl all ≤1; PGA>1 
### Non-remission (TJC28 or SJC28 or CRP mg/dl >1, irrespective of PGA value) 
* p<.05 
**p<.001 
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Table 4 – Multivariable linear regression models to explain PGA according to remission state 
categories in RA patients (n=292) 
CRP = C-reactive protein; HADS = Hospital Anxiety and Depression Scale; PGA = patient global assessment; SJC28 
= swollen joint counts using 28 joints; TIPI = Ten Item Personality Inventory; TJC28 = tender joint counts using 28 
joints. 
# Remission = TJC28, SJC28, CRP mg/dl, and PGA all ≤1   
## Near-remission = TJC28, SJC28, and CRP mg/dl all ≤1; PGA>1  
### Non-remission (TJC28 or SJC28 or CRP mg/dl >1, irrespective of PGA value) 
Variables included in all models: age, disease duration, formal education, Nr of comorbidities, TJC28, SJC28, CRP, 
pain, fatigue, function, HADS anxiety, HADS depression, happiness, TIPI extraversion, TIPI conscientiousness, TIPI 
emotional stability, TIPI openness to experience 
 
 
 
 
  
 
All Patients  
(n=292) 
Remission#  
(n=28) 
Near-remission## 
(n=106) 
Non-Remission### 
(n=158) 
 β stand. p-value β stand. p-value β stand. p-value β stand. p-value 
Pain 
Fatigue 
Function 
HADS-Anxiety 
TJC28 
SJC28 
Formal education 
.28 
.22 
.26 
.16 
-- 
.11 
-.08 
<.001 
<.001 
<.001 
.001 
-- 
.003 
.039 
-- 
.62 
-- 
-- 
.33 
-- 
-- 
-- 
<.001 
-- 
-- 
.024 
-- 
-- 
.25 
.36 
.14 
.16 
-- 
-- 
-- 
.012 
<.001 
.078 
.041 
-- 
-- 
-- 
.32 
-- 
.35 
.25 
-- 
.18 
-.12 
<.001 
-- 
<.001 
<.001 
-- 
<.001 
.030 
R2 adj. .62 .49 .50 .62 
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Table 5 – Multivariable linear regression models to explain pain and fatigue in near-
remission and non-remission state categories in RA patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HADS = Hospital Anxiety and Depression Scale; TIPI = Ten Item Personality 
Inventory;  
# Near-remission = TJC28, SJC28, and CRP mg/dl all ≤1; PGA>1 
## Non-remission (TJC28 or SJC28 or CRP mg/dl >1, irrespective of PGA value) 
Variables included in all models: age, disease duration, formal education, Nr of 
comorbidities, TJC28, SJC28, CRP, pain OR fatigue, function, HADS anxiety, HADS 
depression, happiness, TIPI extraversion, TIPI emotional stability, TIPI openness to 
experience 
 
 
  
 
 
Near-remission# 
(n=106)  
 Non-Remission## 
(n=158) 
  β stand. p-value  β stand. p-value 
P
A
IN
 
Fatigue 
Formal education 
HADS-Anxiety 
TIPI Extraversion 
Function 
Happiness 
.64 
-.16 
.14 
.14 
<.001 
<.026 
.065 
.058 
 .52 
 
.13 
 
.25 
.14 
<.001 
 
.061 
 
<.001 
.029 
R2 adj. .51  .54 
FA
TI
G
U
E 
 Pain 
Function 
TIPI Open. Exp. 
TIPI Emot. Stab. 
HADS-Anxiety 
.58 
.21 
-.16 
-.13 
<.001 
.006 
.091 
.050 
 .50 
.19 
 
 
.20 
<.001 
.006 
 
 
.001 
R2 adj. .53  .55 
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Figure 1 - Proposed concept of remission based on 3v versus 4v Boolean definition in 
rheumatoid arthritis patients, and their therapeutic implications 
 
 
